Hepatitis C Virus
Preclinical Data Presented On New Hepatitis C Protease Inhibitor
Published in Hepatitis Weekly, September 24th, 2007
The poster by Simmen et al. entitled "Preclinical Characterization of TMC435350, a novel macrocyclic inhibitor of the HCV NS3/4A serine protease" demonstrates the ability of the compound to reduce the amount of Hepatitis C virus (HCV) replication in laboratory replicon experiments via protease inhibition. Combination of TMC435350 with interferon is also reported to enhance RNA reduction (>4 logs reduction in the replicon model), and to suppress the appearance of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-09-24)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
Investigate the Hepatitis B Drug Pipeline with New Report - Hepatitis C Virus
Infections - Hepatitis C Drug Pipeline Report Provides Detail on Top 20 Companies with Products in the Early and Late Stage of Development - Hepatitis C Virus
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients - Gene Therapy
Researchers from Tokyo Medical and Dental University report on findings in gene therapy - Hepatitis B Virus
Data on hepatitis B virus reported by researchers at Korea University, Department of Internal Medicine - Hepatitis B Virus
Reports from Nagoya City University describe recent advances in hepatitis B virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
